Impact of Fremanezumab Treatment on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension in a Real-World Setting

被引：0
|
作者：
Tangirala, K. [1 ]
Pedarla, V. [2 ]
Driessen, M. [3 ]
Krasenbaum, L. J. [1 ]
Thompson, S. F. [1 ]
Maughn, K. [2 ]
Seminerio, M. J. [1 ]
Cohen, J. M. [1 ]
机构：
[1] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[2] STATinMED Res, Plano, TX USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0314
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [1] Impact of Fremanezumab Treatment on Clinical Outcomes Among Migraine Patients With Comorbid Depression, Anxiety or Hypertension in a Real-World Setting
    Tangirala, K.
    Pedarla, V.
    Driessen, M.
    Krasenbaum, L. J.
    Thompson, S. F.
    Maughn, K.
    Seminerio, M. J.
    Cohen, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 169 - 169
  • [2] Real-world impact of AJOVY use on clinical outcomes among migraine patients with comorbid depression, anxiety or hypertension
    Tangirala, K.
    Pedarla, V
    Driessen, M. T.
    Krasenbaum, L. J.
    Thompson, S. F.
    Maughn, K.
    Seminerio, M. J.
    Cohen, J. M.
    HEADACHE, 2021, 61 : 71 - 71
  • [3] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS WITH QUARTERLY AND MONTHLY FREMANEZUMAB IN ADULT PATIENTS WITH MIGRAINE IN A US REAL-WORLD SETTING
    Cohen, J.
    Thompson, S.
    Ayyagari, R.
    Driessen, M.
    Seminerio, M.
    Carr, K.
    Yim, E.
    VALUE IN HEALTH, 2022, 25 (01) : S36 - S36
  • [4] Impact of Fremanezumab on Migraine-related Health Care Resource Utilization and Costs in US Patients With Migraine and Comorbid Depression and/or Anxiety
    Buse, Dawn C.
    Driessen, Maurice T.
    Krasenbaum, Lynda J.
    Akcicek, Hasan
    Lyras, Leonidas
    Packnett, Elizabeth R.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 78 - 79
  • [5] TREATMENT PATTERNS AND REAL-WORLD OUTCOMES AMONG PATIENTS WITH EPISODIC MIGRAINE IN CHINA
    Zhao, H.
    Zhang, L.
    Ford, J.
    Li, Z.
    Zhong, S.
    Ye, W.
    Li, J.
    Tockhorn-Heidenreich, A.
    Cotton, S.
    Chen, C.
    VALUE IN HEALTH, 2021, 24 : S171 - S171
  • [6] Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
    Suzuki, Shiho
    Suzuki, Keisuke
    Shiina, Tomohiko
    Haruyama, Yasuo
    Hirata, Koichi
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [7] Impact of Natalizumab on Economic and Clinical Outcomes in MS Patients in the Real-World Setting
    Cai, Qian
    Tan, Hiangkiat
    Agarwal, Sonalee
    Kamat, Siddhesh
    NEUROLOGY, 2010, 74 (09) : A65 - A65
  • [8] Real-world evidence on fremanezumab for migraine treatment in Japan: a retrospective analysis
    Takizawa, T.
    Ohtani, S.
    Watanabe, N.
    Ihara, K.
    Takahashi, N.
    Miyazaki, N.
    Ishizuchi, K.
    Takemura, R.
    Hori, S.
    Nakahara, J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [9] Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting
    Velasco-Juanes F.
    Gómez-Esteban J.C.
    Fernández-Valle T.
    Matute-Nieves A.
    Almeida-Velasco J.
    Lloret-Villas M.I.
    Ugarriza-Serrano I.
    Drugs & Therapy Perspectives, 2018, 34 (7) : 335 - 343
  • [10] Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany
    Heinze, A.
    Totev, T.
    Krasenbaum, L.
    Terasawa, E.
    Akcicek, H.
    Hipp, J.
    Sun, R.
    Yim, E.
    Driessen, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 419 - 419
12345